A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Pneumonia
In brief
This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).
Key facts
- Study ID
- NCT07615010
- Run by
- MiNK Therapeutics
- People needed
- 90
- Starts
- 2026-05-26
- Expected to finish
- 2027-08-01
- Last updated by the study team
- 2026-06-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- First Lviv Territorial Medical Union — Lviv, Ukraine (enrolling)
- UCSF Medical Center at Parnassus Heights — San Francisco, California, United States
- Children's Memorial Hermann Hospital — Houston, Texas, United States
- University Hospital — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.